title: Adverse effects of androgen-deprivation therapy in prostate cancer and their management.
abstract: OBJECTIVE
  To provide an up-to-date summary of current literature on the management of adverse effects of androgen-deprivation therapy (ADT).
  
  
  METHODS
  All relevant medical literature on men with prostate cancer treated with ADT from 2005 to 2014, and older relevant papers, were reviewed. Recent health advisory statements from the Australian government, societies and advocacy groups have been incorporated to the document.
  
  
  RESULTS
  There are numerous adverse effects of ADT that require pro-active prevention and treatment. Ranging from cardiovascular disease, diabetes and osteoporosis, to depression, cognitive decline and sexual dysfunction, the range of adverse effects is wide. Baseline assessment, monitoring, prevention and consultation from a multidisciplinary team are important in minimising the harm from ADT.
  
  
  CONCLUSIONS
  This review provides a series of practical recommendations to assist with managing the adverse effects of ADT.
authors.affiliation: Department of Urology, Princess Alexandra Hospital, QLD, Australia; Australian Prostate Cancer Research Centre, Institute of Health and Biomedical Innovation, Queensland University of Technology, Princess Alexandra Hospital, Translational Research Institute, QLD, Australia.
authors.forename: Handoo
authors.initials: H
authors.lastname: Rhee
authors.forename: Jennifer H
authors.initials: JH
authors.lastname: Gunter
authors.forename: Peter
authors.initials: P
authors.lastname: Heathcote
authors.forename: Ken
authors.initials: K
authors.lastname: Ho
authors.forename: Phillip
authors.initials: P
authors.lastname: Stricker
authors.forename: Niall M
authors.initials: NM
authors.lastname: Corcoran
authors.forename: Colleen C
authors.initials: CC
authors.lastname: Nelson
mesh_terms: D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D064420:Drug-Related Side Effects and Adverse Reactions / Q000517:prevention & control / Q000628:therapy*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*
chemical_list: D000726:Androgen Antagonists; D000970:Antineoplastic Agents
keywords: adverse effect; androgen-deprivation therapy; prostate cancer